We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » HATCH-WAXMAN PATENT REFORM CHANGES BECOMING EVIDENT
The FDA has not received a single polymorph patent for filing in the Orange Book since new drug patent rules went into effect last year, according to FDA officials, who are seeking input on implementing the changes to the Hatch-Waxman Act patent law.